Comparing Intrathecal Chloroprocaine 1% and Ropivacaine 0.75% for Elective Cesarean Section Anesthesia

What this Trial Is About

Researchers are evaluating the effects of two local anesthetics, chloroprocaine 1% and ropivacaine 0.75%, used during elective cesarean sections. This randomized controlled trial aims to compare these drugs when administered intrathecally as part of combined spinal-epidural anesthesia, which is preferred for cesarean deliveries to avoid airway complications associated with general anesthesia. The study investigates how these anesthetics perform in terms of onset, sensory and motor block characteristics, and pain control during surgery. Participants will receive a fixed intrathecal dose of either chloroprocaine 1% or ropivacaine 0.75% during their cesarean section. The study is double-blind and randomized, with two groups receiving one of the anesthetics. Chloroprocaine has a quicker onset and was previously limited by safety concerns, but newer formulations are considered safe. Ropivacaine is commonly used in Greece. The trial focuses on the intraoperative period of the cesarean section under combined spinal-epidural anesthesia. During the study, researchers will monitor the time to achieve different levels of sensory and motor block, pain levels at various surgical stages, and the need for additional pain relief. They will also assess neonatal outcomes such as Apgar scores and blood gases, and record any side effects like nausea, dizziness, or neurological symptoms up to two months after surgery. The participants satisfaction and recovery parameters, including time in the recovery unit and time to mobilization, will also be evaluated. The study is expected to last until January 2026.

Chloroprocaine 1% Versus Ropivacaine 0,75% During Cesarean Section